IRIS
MUSOLINO, Antonino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.502
AS - Asia 4.486
EU - Europa 2.834
SA - Sud America 819
AF - Africa 294
Continente sconosciuto - Info sul continente non disponibili 21
OC - Oceania 5
Totale 12.961
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.348
SG - Singapore 2.321
CN - Cina 1.067
IE - Irlanda 837
BR - Brasile 664
HK - Hong Kong 481
IT - Italia 405
SE - Svezia 398
DE - Germania 345
VN - Vietnam 295
NL - Olanda 216
ZA - Sudafrica 210
FI - Finlandia 112
CA - Canada 94
GB - Regno Unito 88
RU - Federazione Russa 81
IN - India 72
UA - Ucraina 71
AT - Austria 68
AR - Argentina 64
FR - Francia 55
BD - Bangladesh 37
BE - Belgio 37
CI - Costa d'Avorio 34
PL - Polonia 33
MX - Messico 32
TR - Turchia 31
IQ - Iraq 27
EC - Ecuador 25
ES - Italia 25
ID - Indonesia 20
JP - Giappone 20
CL - Cile 17
KR - Corea 17
A1 - Anonimo 16
PK - Pakistan 15
UZ - Uzbekistan 15
CO - Colombia 12
CZ - Repubblica Ceca 12
MA - Marocco 12
VE - Venezuela 12
LT - Lituania 11
PY - Paraguay 10
UY - Uruguay 9
KE - Kenya 8
SA - Arabia Saudita 8
AE - Emirati Arabi Uniti 7
IL - Israele 7
IR - Iran 7
DZ - Algeria 6
EG - Egitto 6
AZ - Azerbaigian 5
DO - Repubblica Dominicana 5
HR - Croazia 5
MY - Malesia 5
NI - Nicaragua 5
OM - Oman 5
RO - Romania 5
EU - Europa 4
NP - Nepal 4
PE - Perù 4
TT - Trinidad e Tobago 4
TW - Taiwan 4
AU - Australia 3
BA - Bosnia-Erzegovina 3
CH - Svizzera 3
HN - Honduras 3
JM - Giamaica 3
JO - Giordania 3
LK - Sri Lanka 3
NG - Nigeria 3
PA - Panama 3
SI - Slovenia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BG - Bulgaria 2
BO - Bolivia 2
GH - Ghana 2
GT - Guatemala 2
HU - Ungheria 2
IS - Islanda 2
LV - Lettonia 2
MK - Macedonia 2
NA - Namibia 2
NZ - Nuova Zelanda 2
RS - Serbia 2
SC - Seychelles 2
SN - Senegal 2
TH - Thailandia 2
AL - Albania 1
AM - Armenia 1
BB - Barbados 1
BH - Bahrain 1
BY - Bielorussia 1
ET - Etiopia 1
GP - Guadalupe 1
GR - Grecia 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
Totale 12.950
Salva come PNG Salva come JPEG
Città #
Singapore 1.180
Dublin 821
Chandler 667
Ashburn 651
Hong Kong 479
Beijing 452
Santa Clara 372
Boardman 219
Dallas 210
Johannesburg 197
Princeton 147
Ann Arbor 140
Shanghai 116
New York 114
Ho Chi Minh City 109
Bremen 105
Los Angeles 92
Des Moines 80
Helsinki 73
Hanoi 66
Parma 65
Munich 62
Jacksonville 60
Seattle 60
Grafing 57
São Paulo 57
Vienna 57
Moscow 55
Wilmington 55
Montreal 49
Hefei 43
Milan 42
Columbus 37
Abidjan 34
Dearborn 32
Brussels 30
Buffalo 29
Nuremberg 29
Nanjing 25
Rio de Janeiro 25
Bologna 24
San Mateo 22
Toronto 22
Brooklyn 21
Frankfurt am Main 20
Stockholm 20
The Dalles 20
Phoenix 19
Shenyang 19
Warsaw 19
Jinan 17
Tokyo 17
Belo Horizonte 16
Haiphong 15
Rome 15
Woodbridge 15
Boston 14
Denver 14
Fairfield 14
London 14
Tashkent 14
Atlanta 13
Curitiba 13
Pune 13
Tianjin 13
Ardea 12
Brasília 12
Changsha 12
Chicago 12
Fremont 12
Poplar 12
Rio Saliceto 12
Amsterdam 11
Houston 11
Salvador 11
Borås 10
Campinas 10
Jakarta 10
Turku 10
Augusta 9
Buenos Aires 9
Charlotte 9
Council Bluffs 9
Izmir 9
Manchester 9
Montevideo 9
Nanchang 9
Ravenna 9
Reggio Emilia 9
Seoul 9
Baghdad 8
Da Nang 8
Dhaka 8
Hebei 8
Mexico City 8
Rockville 8
San Francisco 8
Taiyuan 8
Cape Town 7
Chennai 7
Totale 7.950
Salva come PNG Salva come JPEG
Nome #
Role of immunoglobulin G fragment C receptor polymorphism-mediatedantibody-dependant1. cellular cytotoxicity in colorectal cancer treated withcetuximab therapy. Pharmacogenomics J. 255
SARS-CoV-2 Infection Risk and COVID-19 Prevalence and Mortality in Cancer Patients During the First Wave of COVID-19 Pandemic in a Virus Epicenter in Northern Italy 132
1134 POSTER Survival prediction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 131
Clinico-Immunological Profile of a 67-Year-Old Woman Affected by HER2-Positive Breast Cancer and Autoimmune Dermatomyositis 131
BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: A population-based study 130
Role of immunoglobulin G fragment C receptor polymorphism-mediated antibody-dependant cellular cytotoxicity in colorectal cancer treated with cetuximab therapy 128
The Breast Avastin Trial: Phase II study of bevacizumab maintenance therapy after induction chemotherapy with docetaxel and capecitabine for the first-line treatment of patients with locally recurrent or metastatic breast cancer 125
Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression 124
Alternative academic approaches for testing homologous recombination deficiency in ovarian cancer in the MITO16A/MaNGO-OV2 trial 123
Integrated MRI–Immune–Genomic Features Enclose a Risk Stratification Model in Patients Affected by Glioblastoma 123
[68Ga]Nivolumab: a novel PET tracer to detect PD-1 expressing tumors 123
Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient 122
Abstract P1-14-05: Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE Trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 122
9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER 122
Salivary microRNA for diagnosis of cancer and systemic diseases: A systematic review 121
Prognostic impact of interval breast cancer detection in women with pT1aN0M0 breast cancer with HER2-positive status: results from a multicenter population-based cancer registry study 119
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 118
Biological Role and Clinical Implications of microRNAs in BRCA Mutation Carriers 117
522 POSTER Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFR-expressing metastatic colorectal cancer patients treated with cetuximab-based therapy 116
Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition Testing 116
Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: Final results of the phase III randomized Short-HER study 114
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 114
Role of innate and adaptive immunity in the efficacy of anti-HER2 monoclonal antibodies for HER2-positive breast cancer 113
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 112
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 110
Abstract OT1-03-03: Phase II, open label, randomized, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with operable or locally advanced/Inflammatory HER2-positive breast cancer. ImmunHER trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 110
Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role? 108
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 106
p73 and p53 pathway in human breast cancers. 105
Prognostic impact of interval breast cancer detection in women with pT1a N0M0 breast cancer with HER2-positive status: Results from a multicentre population-based cancer registry study 105
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 102
Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma 101
Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review 99
Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study 98
A review of immune checkpoint blockade in breast cancer 98
Nab-paclitaxel after docetaxel hypersensitivity reaction: case report and literature review 97
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 96
Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/NEU-positive metastatic breast cancer 96
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer. 96
Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large B Cell Non Hodgkin Lymphoma 95
A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes 95
Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study 95
BRCA STATUS, MOLECULAR PROFILE AND CLINICAL VARIABLES IN PRIMARY BILATERAL BREAST CANCERS: A POPULATION-BASED CANCER REGISTRY STUDY 95
My best choice after a round trip from illness 94
Mechanism of action and clinical efficacy of CDK4/6 inhibitors in BRCA-mutated, estrogen receptor-positive breast cancers: Case report and literature review 92
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 90
9 Weeks vs 1 Year Adjuvant Trastuzumab in Combination with Chemotherapy: Preliminary Cardiac Safety Data of the Phase III Multicentric Italian Study ShortHER 90
Survival predisction of terminally ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 89
20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years 89
In reply 88
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer: ERIGE trial on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 87
Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) 87
9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio 86
ACTIVITY AND SAFETY OF DOSEADJUSTED INFUSIONAL CHOP CHEMOTHERAPY WITH RITUXIMAB (DAPOCHR) IN VERY ELDERLY PATIENTS WITH POORPROGNOSTIC UNTREATED DIFFUSE LARGE BCELL NONHODGKIN'S LYMPHOMA 85
A narrative review of the principal glucocorticoids employed in cancer 85
The future potential of genome-wide mutational profiles in HRD detection in breast cancer 84
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer 84
Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force 84
Prognostic significance of germline BRCA mutations in patients with HER2-POSITIVE breast cancer 83
Risk of breast cancer in ovarian cancer patients non-carriers of BRCA1 and BRCA2 mutations with a family history of breast and ovarian cancer: A population-based cancer registry study 82
Prognostic role of immunoglobulin g fragment c receptor polymorphisms in solid tumors 82
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016) 81
La fototerapia mirata bath-puva come trattamento di alcune reazioni cutanee avverse causte da farmaci inibitori delle tirosina-Kinasi (TKI) 81
Hypertriglyceridaemia with bexarotene in cutaneous T-cell lymphoma: The role of omega-3 fatty acids. 81
Functional HRD by RAD51 identifies BRCA1 VUS associated with loss of gene function and response to DNA-damaging agents 79
Long-Term Effects of Breast Cancer Therapy and Care: Calm after the Storm? 78
Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia. 77
Molecular subtypes, metastatic pattern and patient age in breast cancer: An analysis of italian network of cancer registries (airtum) data 77
The relative contribution of the decreasing tumour thickness trend to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation 77
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification 77
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: Results of the randomized phase II CHER-LOB study 76
Brain metastasis (BM) prediction by transcriptomic profiling in triple-negative breast cancer (TNBC) 76
Male breast cancer in Parma Province: Descriptive epidemiology, molecular markers and clinical variables 75
Correlation between HER2/ neu amplification in fine needle aspirates from breast carcinoma and responses to neoadjuvant anthracycline based chemotherapy 75
Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy 74
Prospective biomarker analysis of the randomized CHER-LOB study evaluating the dual anti-HER2 treatment with trastuzumab and lapatinib plus chemotherapy as neoadjuvant therapy for HER2-positive breast cancer 74
Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma 73
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 73
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators 72
Survival prediction of terminally Ill cancer patients by clinical and laboratory parameters: usefullness role of simple prognostic indicators. 70
PARP inhibition increases immune infiltration in homologous recombination repair (HRR)-deficient tumors 69
BRCA1 and BRCA2 status in a sample of Italian women with early onset breast cancer (EOBC) 69
Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2 positive breast cancers 69
Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity. 69
EFFICACY AND SAFETY OF THE ASSOCIATION OF PACLITAXEL AND ESTRAMUSTINE WITH ZOLENDRONIC ACID, IN METASTATIC HORMONE REFRACTORY PROSTATE CARCINOMA 69
Phase II Study of Bevacizumab in Combination with Docetaxel and Capecitabine for the First Line Treatment of Patients with Locally Recurrent or Metastatic Breast Cancer 69
Role of Fcγ receptors in HER2-targeted breast cancer therapy 69
Hormone Receptor-Positive/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies 68
Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial 68
Different expression of BRCA1 status and clinical variables in a sample of Italian women with early onset breast cancer (EOBC) 66
Niraparib for advanced breast cancer with germline BRCA1 and BRCA2 mutations: the EORTC 1307-BCG/BIG5-13/TESARO PR-30-50-10-C BRAVO study 64
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients 63
https://researchopenworld.com/at-doctor-level/# 63
Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy 63
DIFFERENT EXPRESSION OF BRCA1 STATUS AND CLINICAL VARIABLES IN A SAMPLE OF ITALIAN WOMEN WITH EARLY ONSET BREAST CANCER (EOBC) 62
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 61
Brain Metastasis Prediction by Transcriptomic Profiling in Triple-Negative Breast Cancer 61
Reply to Activity and Safety of DoseAdjusted Infusional Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Chemotherapy With Rituximab in Very Elderly Patients With PoorPrognostic Untreated Diffuse Large BCell NonHodgkin Lymphoma 61
Immunoglobulin G fragment C receptor polymorphisms and clinical outcome of EGFRexpressing metastatic colorectal cancer patients treated with cetuximab based therapy 61
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer 60
Totale 9.269
Salva come PNG Salva come JPEG
Categoria #
all - tutte 59.027
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 59.027
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021273 0 0 0 0 0 25 43 35 68 12 70 20
2021/2022622 23 11 24 28 16 67 32 42 41 26 26 286
2022/20232.680 328 196 134 177 260 255 18 183 952 23 122 32
2023/20241.097 53 112 16 32 97 225 106 117 40 79 64 156
2024/20253.531 70 209 285 171 394 315 91 114 476 383 293 730
2025/20264.091 660 754 906 589 988 194 0 0 0 0 0 0
Totale 13.214